Ondine Biomedical Inc. Launches Steriwave Pilot at King's College Hospital

Ondine Biomedical Inc., a Canadian company known for light-activated antimicrobial treatments, has announced an upcoming pilot of its Steriwave technology at King's College Hospital (KCH) in London. KCH plans to incorporate Steriwave into a quality improvement initiative aimed at reducing hospital-acquired infections. The pilot is set to commence later this year.

Steriwave is a novel treatment that utilizes a light-activated agent to eradicate infection-causing pathogens effectively. Applied via nasal swab followed by red light laser activation, the treatment promises pathogen destruction without resistance development, presenting an alternative to antibiotics.

Previously, Steriwave was adopted by Mid Yorkshire Teaching NHS Trust and added to the NHS Supply Chain, enhancing accessibility across England and Wales.